Search Results - "Nagira, Yu"

Antidermatophyte activity and PK/PD of ME1111 in a guinea pig model of tinea corporis by Takei-Masuda, Naomi, Nagira, Yu, Kubota-Ishida, Natsuki, Chikada, Tsubasa, Tabata, Yuji, Maebashi, Kazunori

“…Onychomycosis, a superficial fungal infection of the nails, is prevalent in many areas of the world. Topical agents for onychomycosis need to reach the…”
Get full text

In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis by Kubota-Ishida, Natsuki, Takei-Masuda, Naomi, Kaneda, Kaori, Nagira, Yu, Chikada, Tsubasa, Nomoto, Masahiro, Tabata, Yuji, Takahata, Sho, Maebashi, Kazunori, Hui, Xiaoying, Maibach, Howard I

“…ME1111 is a novel antifungal agent currently under clinical development as a topical onychomycosis treatment. A major challenge in the application of topical…”
Get full text

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution by Bhavnani, Sujata M, Hammel, Jeffrey P, Lakota, Elizabeth A, Safir, M Courtney, VanScoy, Brian D, Nagira, Yu, Rubino, Christopher M, Sato, Nobuo, Koresawa, Tomokazu, Kondo, Kenichiro, Ambrose, Paul G

“…ME1100 (arbekacin inhalation solution) is an inhaled aminoglycoside that is being developed to treat patients with hospital-acquired and ventilator-associated…”
Get full text

1279. In Vitro Activity of Nacubactam (OP0595) Alone and in Combination with β-Lactams against β-Lactamase-Producing Enterobacterales Isolated in Japan by Nagira, Yu, Yamada, Keiko, Okade, Hayato, Senju, Nami, Tsutsumi, Yuko, Tabata, Yuji, Kato, Kazuhiko

“…Abstract Background Nacubactam (NAC) is a novel serine β-lactamase inhibitor in clinical development, and inhibits Ambler class A, class C, and some class D…”
Get full text

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection by Bhavnani, Sujata M, Hammel, Jeffrey P, Lakota, Elizabeth A, VanScoy, Brian D, Nagira, Yu, Rubino, Christopher M, Sato, Nobuo, Koresawa, Tomokazu, Kondo, Kenichiro, Ambrose, Paul G

“…Abstract Background ME1100 (arbekacin inhalational solution) is an inhaled aminoglycoside being developed to treat patients with hospital-acquired and…”
Get full text

1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM) by VanScoy, Brian D, Lakota, Elizabeth A, Bhavnani, Sujata M, Giesel, Greg, Carranco, Ana I, Nagira, Yu, Ouchi, Shohei, Kondo, Kenichiro, Ambrose, Paul G

“…Abstract Background ME1100 (arbekacin inhalational solution) is an aminoglycoside in clinical development for the treatment of patients with hospital-acquired…”
Get full text